B-cell Non-Hodgkin’s Lymphoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

B-cell Non-Hodgkin’s Lymphoma Emerging Therapy and TPP Insights

Thelansis’s “B-cell Non-Hodgkin’s Lymphoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

B-cell Non-Hodgkin’s Lymphoma Overview

B-cell non-Hodgkin lymphoma (B-cell NHL) is a group of cancers arising from abnormal B lymphocytes, with behavior ranging from indolent to aggressive. Patients may develop painless enlarged lymph nodes, fever, night sweats, weight loss, fatigue, or extranodal symptoms; some indolent forms are found incidentally. Diagnosis requires tissue biopsy, immunophenotyping, and subtype-specific testing. Treatment depends on histology, stage, molecular features, symptoms, and fitness; options include active surveillance, radiotherapy, anti-CD20 antibodies, chemoimmunotherapy, and targeted agents. For relapsed or refractory disease, CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates provide options in selected subtypes. However, benefits and risks differ across lymphoma types, and resistance or relapse remains a concern. Progress depends on matching treatment to disease biology while improving durability and reducing toxicity. Care depends on subtype.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)